CytoMed Therapeutics Limited Ordinary Shares (GDTC) — Long-term Investment Intensity
CytoMed Therapeutics Limited Ordinary Shares (GDTC) has a Long-term Investment Intensity of 0.2% as of December 2025. Long-term investments of $18.21K represent 0.2% of total assets of $7.98 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. See CytoMed Therapeutics Limited Ordinary Sh shareholders equity for net asset value and shareholders' equity analysis.
LT Investment Intensity
Long-term Investments
Total Assets
Country
CytoMed Therapeutics Limited Ordinary Shares Long-term Investment Intensity (2021–2025)
This chart shows how CytoMed Therapeutics Limited Ordinary Shares's Long-term Investment Intensity has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the intensity stands at 0.2%, reflecting long-term investments of $18.21K against total assets of $7.98 Million USD. Also explore CytoMed Therapeutics Limited Ordinary Sh total assets for the complete picture of this company's asset base.
Annual Long-term Investment Intensity for CytoMed Therapeutics Limited Ordinary Shares (2021–2025)
The table below presents the year-by-year Long-term Investment Intensity for CytoMed Therapeutics Limited Ordinary Shares from 2021 to 2025, covering 5 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see market cap of CytoMed Therapeutics Limited Ordinary Sh.
| Year | LT Investment Intensity | LT Investments (USD) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2025 | 0.2% | $18.21K | $7.98 Million | ▼ -2.8 pp |
| 2024 | 3.0% | $220.95K | $7.37 Million | ▲ +0.9 pp |
| 2023 | 2.1% | $195.07K | $9.37 Million | ▼ -4.1 pp |
| 2022 | 6.1% | $239.42K | $3.90 Million | ▲ +0.1 pp |
| 2021 | 6.1% | $272.97K | $4.51 Million | — |